Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials
Unlike tirzepatide that retains GCG function via counteracting that of GLP-1 through activation of GIPR, causing a glucagonotropic action by stimulating GCG release in states of hypoglycemia 7,49 , peptide 20 is capable of activating GCGR directly
pmid:23931758 46
INCRETIN-BASED THERAPIES FDA APPROVED FOR WEIGHT MANAGEMENT The FDA has approved several incretin hormonebased pharmacotherapeutic agents, including liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, tirzepatide, and orforglipron
These cells generate the new oligodendrocytes that remyelinate axons
Patients with uncontrolled thyroid disease should stabilize their thyroid function before initiating GLP-1 therapy